Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 890

1.

Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.

Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1999 Nov;21(9):633-44.

PMID:
10669911
2.

Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.

Alvarez XA, Pichel V, Pérez P, Laredo M, Corzo D, Zas R, Fernández-Novoa L, Sempere JM, Díaz J, Cacabelos R.

Methods Find Exp Clin Pharmacol. 2000 Sep;22(7):585-94.

PMID:
11196347
4.

Apolipoprotein E genotype and gender influence response to tacrine therapy.

Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S.

Ann N Y Acad Sci. 1996 Dec 16;802:101-10.

PMID:
8993489
6.

Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial.

Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M.

J Clin Pharm Ther. 2003 Feb;28(1):53-9.

PMID:
12605619
7.

Citicoline: pharmacological and clinical review, 2006 update.

Secades JJ, Lorenzo JL.

Methods Find Exp Clin Pharmacol. 2006 Sep;28 Suppl B:1-56. Review.

PMID:
17171187
8.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group.

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
10.

Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors.

Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Alvarez XA.

Ann N Y Acad Sci. 1996 Jan 17;777:399-403.

PMID:
8624120
11.

Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease.

Franco-Maside A, Caamaño J, Gómez MJ, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1994 Oct;16(8):597-607.

PMID:
7760585
12.

"Brain-specific" nutrients: a memory cure?

McDaniel MA, Maier SF, Einstein GO.

Nutrition. 2003 Nov-Dec;19(11-12):957-75. Review.

PMID:
14624946
13.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT.

Neurology. 1998 Jan;50(1):136-45.

PMID:
9443470
14.

CDP-choline: pharmacological and clinical review.

Secades JJ, Frontera G.

Methods Find Exp Clin Pharmacol. 1995 Oct;17 Suppl B:1-54. Review.

PMID:
8709678
16.

Metrifonate treatment of AD: influence of APOE genotype.

Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B.

Neurology. 1999 Dec 10;53(9):2010-6.

PMID:
10599773
18.

Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).

Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR.

Alzheimer Dis Assoc Disord. 1998 Dec;12(4):304-12.

PMID:
9876958
19.

Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.

Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C.

Curr Alzheimer Res. 2005 Jul;2(3):343-53.

PMID:
15974900
20.

A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients.

Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE; Citicoline Stroke Study Group.

Neurology. 2001 Nov 13;57(9):1595-602.

PMID:
11706098

Supplemental Content

Support Center